Business
Confirmation of Q1 trading update
CelLBxHealth plc has announced that it will release its trading update for the first quarter of 2026 in mid-May. The company, specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology, will provide an update on its performance. Disclaimer*
About this update from Cellbxhealth Plc
CelLBxHealth plc ("CelLBxHealth" or "the Company") Confirmation of Q1 trading update Guildford, UK and Plymouth Meeting, U.S. - 30 April 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, announces that it will provide a trading update for Q1 2026 in mid-May. For further information: CelLBxHealth plc Peter Collins, Chief Executive Officer Jan Groen, Executive Chairman [email protected] via Walbrook PR Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales) +44 (0)20 7220 0500 Walbrook PR (Investor and Media Relations) Paul McManus / Alice Woodings Tel: +44 (0)20 7933 8780 or [email protected] Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 About CelLBxHealth plc CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows. Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development. For more information, visit https://cellbxhealth.com/ .